Message #20 From:
NewsBot Date: November 14, 2005 02:00:00 AM
RGBI News International Symposium Features Latest CMI(TM) Data
FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--Nov. 14, 2005--Varese, Italy, was the site of an international symposium focused on Healing Response and Tissue Engineering. Several presentations featured the CMI from ReGen Biologics, Inc. (OTC:RGBI), including two live CMI surgeries. The CMI is a type I collagen implant designed to facilitate growth of new tissue to replace removed or missing meniscus tissue in the human knee.
"This symposium provided an excellent opportunity for surgeons to present and discuss the latest data on meniscus injury and treatment options, as well as a forum to review the newest CMI clinical results and recent advancements in surgical technique," commented William Rodkey, Chief Scientific Officer for ReGen Biologics. "We appreciate the academic organization by the Department of Orthopedic Science and Traumatology 'Mario Boni', of the University of Insubria-Varese," continued Dr. Rodkey.
The symposium faculty included well-known orthopedic surgeons and academicians from Belgium, Italy, Germany, Spain, and the United States. Over 70 physicians, physiotherapists, and practice nurses attended.
Commenting on the meeting, Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics added, "There is tremendous interest in restoring meniscus tissue among orthopedic and sports medicine surgeons and patients. The attendance at this meeting is a clear reflection of that interest. We're pleased with the association of such a distinguished faculty and Xmedica, ReGen's distribution partner in Italy."
A summary of the meeting, including key conclusions from the presentations, will be prepared by the company for distribution to European physicians unable to attend the symposium. The summary will also be available on the ReGen website under the "Events" section.
About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first product using its patented core technology is the CMI, which uses the body's own healing process to grow new tissue in the meniscus, and restore activity levels for patients with meniscus loss. The Company's Multicenter Pivotal Clinical Trial is the largest clinical trial ever conducted involving the human meniscus. The manufacturing module was submitted to the FDA in Q3 2004. The Company expects to conclude the PMA submission with the filing of the CMI clinical module, targeted by year end 2005.
ReGen is headquartered in Franklin Lakes, NJ, and manufactures the CMI in its ISO Certified facility located in Redwood City, CA. For more information on ReGen, visit www.regenbio.com.
